FIGURE 7.

Heart‐derived CSCs‐loaded PVA microneedles for treating MI. (A) Illustration of the overall design of MN‐CSCs. (B) Masson's trichrome staining of heart morphology and fibrosis 3 weeks after applied with different conditions (red: viable tissue; blue: scar tissue). (C,D) Quantitative analyses of infarct wall thickness and viable tissue in the risk area based on Masson's trichrome staining. (E,F) LVEFs measured by echocardiography at 4 h (baseline) and 3 weeks (endpoint) after MI. ^* p < 0.05 when compared with the MI group; ^# p < 0.05 when compared with the MI + MN group; ^& p < 0.05 when compared with the MI + CSC group. Reproduced with permission under a Creative Commons CC BY‐NC License.^{[ 84 ]} Copyright 2018, American Association for the Advancement of Science